


CLAIMS

What is claimed is:

1. A compound represented by:



Formula I

or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof, wherein:

A is selected from the group consisting of phenyl and a 5 or 6-member or heteroaryl;

W is CH or N;

R¹ is selected from the group consisting of halogen, cyano, C₁-C₅alkyl, and C₃-C₅cycloalkyl, wherein C₁-C₅alkyl and C₃-C₅cycloalkyl may be optionally substituted by one, two or three independent occurrences of fluorine;

R² is selected from the group consisting of halogen, cyano, C₁-C₅alkyl, C₃-C₆cycloalkyl, C₂-C₅alkenyl, C₂-C₅alkynyl, C₁-C₅alkoxy, and C₁-C₅alkoxy-C₂-C₅alkyl, wherein each C₁-C₅alkyl, C₃-C₆cycloalkyl, C₂-C₅alkenyl, C₂-C₅alkynyl, and C₁-C₅alkoxy may be optionally substituted by one, two, or three independent occurrences of fluorine or cyano;

R³ is selected from the group consisting of H, C₁-C₃alkyl, and C₃-C₅cycloalkyl, wherein C₁-C₃alkyl and C₃-C₅cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R⁴ is selected from the group consisting of B, D, NR⁶R⁹, NR⁶-(C(R¹⁰)₂)ₚ-NR⁶R⁹, C(O)-NR⁶R⁹, C(O)-B, C(O)-D, and CN;

B is selected from an N-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen and heteroaryl, wherein B may be optionally substituted on one or more available carbons by R⁷ and may be optionally substituted on an available nitrogen by R⁹;

D is selected from a C-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen and heteroaryl, wherein D may be optionally

substituted on one or more available carbons by R^7 and may be optionally substituted on an available nitrogen by R^9 ;

each occurrence of R^7 is independently selected from the group consisting of H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, cyano, and $(C(R^{10})_2)_h-NR^6R^9$, wherein C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine, or two R^7 are joined together with the atom to which they are attached to form oxo;

R^6 is selected from the group consisting of H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_5 alkoxy- C_2 - C_5 alkyl, $C(=O)R^5$, SO_2R^5 , C-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen, and heteroaryl, wherein C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^9 is selected from the group consisting of H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_5 alkoxy- C_2 - C_5 alkyl, $C(=O)R^5$, SO_2R^5 , C-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen, and heteroaryl, wherein C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^5 is selected from the group consisting of H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, and heterocyclyl, wherein C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

each occurrence of R^{10} is independently selected from the group consisting of H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine, or two R^{10} are joined together with the carbon to which they are attached to form a C_3 - C_5 cycloalkyl;

R^L is selected from the group consisting of C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl, $NR^{11}R^{12}$,

and $\left(\begin{array}{c} \text{---} \\ | \\ R^{34} \text{---} U \text{---} R^{34} \\ | \quad | \\ R^{34} \text{---} V \text{---} R^{34} \end{array} \right)_q$, wherein each C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by 1, 2, or 3 independent occurrences of fluorine;

U is N or CR^{13} ;

V is selected from the group consisting of oxygen, $C(R^{34})_2$, and NR^6 ;

r is 0, 1, or 2;

q is 1, 2, or 3;

R^{11} is selected from the group consisting of H, C₁-C₃alkyl, and C₃-C₅cycloalkyl, wherein C₁-C₃alkyl and C₃-C₅cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^{12} is selected from the group consisting of H, C₁-C₃alkyl, and C₃-C₅cycloalkyl, wherein C₁-C₃alkyl and C₃-C₅cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^{13} is selected from H and C₁-C₃alkyl;

each occurrence of R^{34} is independently selected from H, C₁-C₃alkyl, and C₃-C₅cycloalkyl, wherein C₁-C₃alkyl and C₃-C₅cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine, or two R^{34} are joined together with the carbon to which they are attached to form a C₃-C₆cycloalkyl;

L is $-(C(R^{10}))_m-$;

h is 1, 2, or 3;


m is 0, 1, 2, or 3;

n is 2, 3, or 4; and

p is 2 or 3;

provided that when m is 0, R^4 is C-linked to ring A, when m is 1, R^4 is C-linked to L, and when m is 2 or 3, R^4 is N-linked or C-linked to L; and further provided that when r is 0 and q is 1, then U is not CR¹³ and V is not O, and when r or q is 1, then U is not N and V is not O or NR⁶.

2. A compound represented by:



Formula IA

or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof, wherein:

W is CH or N;

X is CH or N;

Y is C(R³³) or N;

R^1 is selected from the group consisting of halogen, cyano, C_1 - C_5 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_5 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one, two or three independent occurrences of fluorine;

R^2 is selected from the group consisting of halogen, cyano, C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl, C_2 - C_5 alkenyl, C_2 - C_5 alkynyl, C_1 - C_5 alkoxy, and C_1 - C_5 alkoxy- C_2 - C_5 alkyl, wherein each C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl, C_2 - C_5 alkenyl, C_2 - C_5 alkynyl, and C_1 - C_5 alkoxy may be optionally substituted by one, two, or three independent occurrences of fluorine or cyano;

R^3 is selected from the group consisting of H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^{33} is selected from the group consisting of H, halogen, C_1 - C_6 alkyl, and C_1 - C_6 alkoxy, wherein C_1 - C_6 alkyl and C_1 - C_6 alkoxy may be optionally substituted by one or more independent occurrences of fluorine;

R^4 is selected from the group consisting of B, D, NR^6R^9 , $NR^6-(C(R^{10})_2)_p-NR^6R^9$, $C(O)-NR^6R^9$, $C(O)-B$, $C(O)-D$, and CN;

B is selected from an N-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen and heteroaryl, wherein B may be optionally substituted on one or more available carbons by R^7 and may be optionally substituted on an available nitrogen by R^9 ;

D is selected from a C-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen and heteroaryl, wherein D may be optionally substituted on one or more available carbons by R^7 and may be optionally substituted on an available nitrogen by R^9 ;

each occurrence of R^7 is independently selected from the group consisting of H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, cyano, and $(C(R^{10})_2)_h-NR^6R^9$, wherein C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine, or two R^7 are joined together with the atom to which they are attached to form oxo;

R^6 is selected from the group consisting of H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_5 alkoxy- C_2 - C_5 alkyl, $C(=O)R^5$, SO_2R^5 , C-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen, and heteroaryl, wherein C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^9 is selected from the group consisting of H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_5 alkoxy- C_2 - C_5 alkyl, $C(=O)R^5$, SO_2R^5 , C-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen, and heteroaryl, wherein C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^5 is selected from the group consisting of H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, and heterocyclyl, wherein C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

each occurrence of R^{10} is independently selected from the group consisting of H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine, or two R^{10} are joined together with the carbon to which they are attached to form a C_3 - C_5 cycloalkyl;

R^L is selected from the group consisting of C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl, $NR^{11}R^{12}$,

and $\left(\begin{array}{c} \text{---} \\ | \\ R^{34} \text{---} U \text{---} R^{34} \\ | \quad | \\ R^{34} \text{---} V \text{---} R^{34} \end{array} \right)_q$, wherein each C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by 1, 2, or 3 independent occurrences of fluorine;

U is N or CR^{13} ;

V is selected from the group consisting of oxygen, $C(R^{34})_2$, and NR^6 ;

r is 0, 1, or 2;

q is 1, 2, or 3;

R^{11} is selected from the group consisting of H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^{12} is selected from the group consisting of H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^{13} is selected from H and C_1 - C_3 alkyl;

each occurrence of R^{34} is independently selected from H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine, or two R^{34} are joined together with the carbon to which they are attached to form a C_3 - C_6 cycloalkyl;

L is $-(C(R^{10})_2)_m$;

h is 1, 2, or 3;


m is 0, 1, 2, or 3;

n is 2, 3, or 4; and

p is 2 or 3;


provided that both of X and Y are not N, when r is 0 and q is 1, then U is not CR¹³ and V is not O, and when r or q is 1, then U is not N and V is not O or NR⁶.

3. The compound of claim 1 or claim 2, wherein W is N.
4. The compound of any one of claims 1-3, wherein X is CH and Y is N.
5. The compound of any one of claims 1-3, wherein X is CH and Y is C(R³³).
6. The compound of any one of claims 1-5, wherein R⁴ is B.
7. The compound of any one of claims 1-6, wherein R⁴ is selected from the group consisting of:




wherein u is 1, 2, or 3.


8. The compound of any one of claims 1-7, wherein R⁴ is selected from the group consisting of:



9. The compound of any one of claims 1-8, wherein R⁴ is selected from the group consisting of:




10. The compound of any one of claims 1-7, wherein R^4 is selected from the group consisting of:



11. The compound of any one of claims 1-5, wherein R^4 is D.

12. The compound of any one of claims 1-5 or claim 11, wherein R^4 is selected from the group consisting of:




13. The compound of any one of claims 1-12, wherein L is $-(CH_2)_m$.

14. The compound of any one of claims 1-13, wherein m is 0.

15. The compound of any one of claims 1-14, wherein R^1 is selected from the group consisting of halogen, C_1 - C_5 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_5 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted with one, two, or three independent occurrences of fluorine.
16. The compound of any one of claims 1-15, wherein R^1 is CF_3 .
17. The compound of any one of claims 1-15, wherein R^1 is CF_2H .
18. The compound of any one of claims 1-15, wherein R^1 is selected from the group consisting of chloro, bromo, and fluoro.
19. The compound of claim 18, wherein R^1 is bromo.
20. The compound of any one of claims 1-15, wherein R^1 is cyclopropyl.
21. The compound of any one of claims 1-20, wherein R^2 is selected from the group consisting of C_3 - C_5 cycloalkyl, C_1 - C_5 alkyl, halogen, CN, C_2 - C_5 alkenyl, and C_2 - C_5 alkynyl, wherein C_3 - C_5 cycloalkyl, C_1 - C_5 alkyl, C_2 - C_5 alkenyl, and C_2 - C_5 alkynyl may be optionally substituted with one, two, or three independent occurrences of fluorine.
22. The compound of any one of claims 1-21, wherein R^2 is selected from the group consisting of C_{1-2} alkyl and C_{3-4} cycloalkyl.
23. The compound of any one of claims 1-22, wherein R^3 is selected from the group consisting of H and C_1 - C_3 alkyl, wherein C_1 - C_3 alkyl may be optionally substituted by one or more independent occurrences of fluorine.
24. The compound of any one of claims 1-23, wherein R^L is selected from the group consisting of C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl, each of which may be optionally substituted by 1, 2, or 3 independent occurrences of fluorine.
25. The compound of any one of claims 1-24, wherein R^L is cyclobutyl.


26. The compound of any one of claims 1-23, wherein R^L is $NR^{11}R^{12}$.



27. The compound of any one of claims 1-24, wherein R^L is $\left(\begin{array}{c} \text{R}^{34} \\ \text{U} \\ \text{R}^{34} \end{array} \right)_q$, wherein each C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by 1, 2, or 3 independent occurrences of fluorine; U is N or CR^{13} ; V is selected from the group consisting of oxygen, $C(R^{34})_2$, and NR^6 ; r is 0, 1, or 2; q is 1, 2, or 3; R^{13} is selected from H and C_1 - C_3 alkyl; and each occurrence of R^{34} is independently selected from H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine, or two R^{34} are joined together with the carbon to which they are attached to form a C_3 - C_6 cycloalkyl; provided that when r is 0 and q is 1, then U is not CR^{13} and V is not O, and when r or q is 1, then U is not N and V is not O or NR^6 .

28. The compound of any one of claims 1-27, wherein n is 3.

29. A compound represented by:



Formula IB

or a pharmaceutically acceptable salt thereof, wherein:


n is 2, 3, or 4;

R^1 is selected from the group consisting of halogen, cyano, C_1 - C_5 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_5 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one, two or three independent occurrences of fluorine;

R^2 is selected from the group consisting of C_1 - C_2 alkyl and C_3 - C_4 cycloalkyl, and halogen, wherein C_1 - C_2 alkyl and C_3 - C_4 cycloalkyl may be optionally substituted by one, two or three independent occurrences of fluorine;

R^3 is selected from the group consisting of H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^4 is selected from the group consisting of:



R^9 is selected from the group consisting of H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, $C(=O)R^5$, SO_2R^5 , C-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen and heteroaryl, wherein C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^5 is selected from the group consisting of H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, and heterocyclyl, wherein C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

each occurrence of R^7 is independently selected from the group consisting of H, C_1 - C_6 alkyl, and C_3 - C_6 cycloalkyl, wherein C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine, or two R^7 are joined together with the atom to which they are attached to form oxo;

R^L is selected from the group consisting of C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl, $NR^{11}R^{12}$,

and $\left(\begin{array}{c} \text{---} \\ | \\ R^{34} \text{---} U \text{---} R^{34} \\ | \\ R^{34} \text{---} V \text{---} R^{34} \end{array} \right)_q$, wherein each C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by 1, 2, or 3 independent occurrences of fluorine;

U is N or CR^{13} ;

V is selected from the group consisting of oxygen, $C(R^{34})_2$, and NR^6 ;

r is 0, 1, or 2;

q is 1, 2, or 3;

R^6 is selected from the group consisting of H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, $C(=O)R^5$, SO_2R^5 , C-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen and heteroaryl, wherein C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^{11} is selected from the group consisting of H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;


R^{12} is selected from the group consisting of H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^{13} is selected from H and C_1 - C_3 alkyl; and

each occurrence of R^{34} is independently selected from H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine, or two R^{34} are joined together with the carbon to which they are attached to form a C_3 - C_6 cycloalkyl;

provided that both of X and Y are not N, when r is 0 and q is 1, then U is not CR^{13} and V is not O, and when r or q is 1, then U is not N and V is not O or NR^6 .

30. A compound represented by:



Formula IC

or a pharmaceutically acceptable salt thereof, wherein:


n is 2, 3, or 4;

R^1 is selected from the group consisting of halogen, cyano, C_1 - C_5 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_5 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one, two or three independent occurrences of fluorine;

R^2 is selected from the group consisting of C_1 - C_2 alkyl and C_3 - C_4 cycloalkyl, and halogen, wherein C_1 - C_2 alkyl and C_3 - C_4 cycloalkyl may be optionally substituted by one, two or three independent occurrences of fluorine;

R^3 is selected from the group consisting of H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^4 is selected from the group consisting of:



R^9 is independently selected from the group consisting of H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, $C(=O)R^5$, SO_2R^5 , C-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen and heteroaryl, wherein C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^5 is selected from the group consisting of H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, and heterocyclyl, wherein C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

each occurrence of R^7 is independently selected from the group consisting of H, C_1 - C_6 alkyl, and C_3 - C_6 cycloalkyl, wherein C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine, or two R^7 are joined together with the atom to which they are attached to form oxo;

R^L is selected from the group consisting of C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl, $NR^{11}R^{12}$,

and $\left(\begin{array}{c} \text{---} \\ | \\ R^{34} \text{---} U \text{---} R^{34} \\ | \quad | \\ R^{34} \text{---} V \text{---} R^{34} \end{array} \right)_q$, wherein each C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by 1, 2, or 3 independent occurrences of fluorine;

U is N or CR^{13} ;

V is selected from the group consisting of oxygen, $C(R^{34})_2$, and NR^6 ;

r is 0, 1, or 2;

q is 1, 2, or 3;

R^6 is selected from the group consisting of H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, $C(=O)R^5$, SO_2R^5 , C-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen and heteroaryl, wherein C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^{11} is selected from the group consisting of H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;


R^{12} is selected from the group consisting of H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^{13} is selected from H and C_1 - C_3 alkyl; and

each occurrence of R^{34} is independently selected from H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine, or two R^{34} are joined together with the carbon to which they are attached to form a C_3 - C_6 cycloalkyl;

provided that both of X and Y are not N, when r is 0 and q is 1, then U is not CR^{13} and V is not O, and when r or q is 1, then U is not N and V is not O or NR^6 .


31. A compound represented by:



Formula ID

or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof, wherein:

ring DD is selected from the group consisting of



W is CH or N;

R^1 is selected from the group consisting of halogen, cyano, C_1 - C_5 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_5 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one, two or three independent occurrences of fluorine;

R^2 is selected from the group consisting of halogen, cyano, C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl, C_2 - C_5 alkenyl, C_2 - C_5 alkynyl, C_1 - C_5 alkoxy, and C_1 - C_5 alkoxy- C_2 - C_5 alkyl, wherein each C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl, C_2 - C_5 alkenyl, C_2 - C_5 alkynyl, and C_1 - C_5 alkoxy may be optionally substituted by one, two, or three independent occurrences of fluorine or cyano;

R^3 is selected from the group consisting of H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^4 is selected from the group consisting of B, D, NR^6R^9 , $NR^6-(C(R^{10})_2)_p-NR^6R^9$, $C(O)-NR^6R^9$, $C(O)-B$, $C(O)-D$, and CN;

B is selected from an N-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen and heteroaryl, wherein B may be optionally substituted on one or more available carbons by R^7 and may be optionally substituted on an available nitrogen by R^9 ;

D is selected from a C-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen and heteroaryl, wherein D may be optionally substituted on one or more available carbons by R^7 and may be optionally substituted on an available nitrogen by R^9 ;

each occurrence of R^7 is independently selected from the group consisting of H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, cyano, and $(C(R^{10})_2)_h-NR^6R^9$, wherein C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine, or two R^7 are joined together with the atom to which they are attached to form oxo;

R^6 is selected from the group consisting of H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_5 alkoxy- C_2 - C_5 alkyl, $C(=O)R^5$, SO_2R^5 , C-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen, and heteroaryl, wherein C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^9 is selected from the group consisting of H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_5 alkoxy- C_2 - C_5 alkyl, $C(=O)R^5$, SO_2R^5 , C-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen, and heteroaryl, wherein C_1 -

C₆alkyl and C₃-C₆cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R⁵ is selected from the group consisting of H, C₁-C₆alkyl, C₃-C₆cycloalkyl, and heterocyclyl, wherein C₁-C₆alkyl and C₃-C₆cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

each occurrence of R¹⁰ is independently selected from the group consisting of H, C₁-C₃alkyl, and C₃-C₅cycloalkyl, wherein C₁-C₃alkyl and C₃-C₅cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine, or two R¹⁰ are joined together with the carbon to which they are attached to form a C₃-C₅cycloalkyl;

R^L is selected from the group consisting of C₁-C₆alkyl and C₃-C₆cycloalkyl, NR¹¹R¹²,

and $\left(\begin{array}{c} \text{---} \\ | \\ \text{R}^{34} \text{---} \text{U} \text{---} \text{R}^{34} \\ | \quad | \\ \text{R}^{34} \text{---} \text{V} \text{---} \text{R}^{34} \end{array} \right)_q$, wherein each C₁-C₆alkyl and C₃-C₆cycloalkyl may be optionally substituted by 1, 2, or 3 independent occurrences of fluorine;

U is N or CR¹³;

V is selected from the group consisting of oxygen, C(R³⁴)₂, and NR⁶;

r is 0, 1, or 2,

q is 1, 2, or 3;

R¹¹ is selected from the group consisting of H, C₁-C₃alkyl, and C₃-C₅cycloalkyl, wherein C₁-C₃alkyl and C₃-C₅cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R¹² is selected from the group consisting of H, C₁-C₃alkyl, and C₃-C₅cycloalkyl, wherein C₁-C₃alkyl and C₃-C₅cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R¹³ is selected from H and C₁-C₃alkyl;

each occurrence of R³⁴ is independently selected from H, C₁-C₃alkyl, and C₃-C₅cycloalkyl, wherein C₁-C₃alkyl and C₃-C₅cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine, or two R³⁴ are joined together with the carbon to which they are attached to form a C₃-C₆cycloalkyl;

L is -(C(R¹⁰)₂)_m-;

h is 1, 2, or 3;

m is 0, 1, 2, or 3;

n is 2, 3, or 4; and


p is 2 or 3;

provided that when m is 0, R⁴ is C-linked to the pyrazolyl ring, when m is 1, R⁴ is C-linked to L, and when m is 2 or 3, R⁴ is N-linked or C-linked to L; and further provided that when r is 0 and q is 1, then U is not CR¹³ and V is not O, and when r or q is 1, then U is not N and V is not O or NR⁶.


32. The compound of claim 31, wherein W is N.

33. The compound of claim 31, wherein W is CH.


34. The compound of any one of claims 31-33, wherein ring DD is selected from the group consisting of:




35. The compound of any one of claims 31-33, wherein ring DD is selected from the group consisting of:



36. The compound of any one of claims 31-33, wherein ring DD is:




37. The compound of any one of claims 31-33, wherein ring DD is:




38. The compound of any one of claims 31-37, wherein R⁴ is D.


39. The compound of any one of claims 31-38, wherein R⁴ is selected from the group consisting of:



40. The compound of any one of claims 31-39, wherein R⁴ is selected from the group consisting of:




41. The compound of any one of claims 31-37, wherein R⁴ is B.
42. The compound of any one of claims 31-37 or claim 41, wherein R⁴ is selected from the group consisting of:




wherein u is 1 or 2.

43. The compound of any one of claims 31-37 or claim 41, wherein R⁴ is selected from the group consisting of:



44. The compound of any one of claims 31-37 or claim 41, wherein R^4 is selected from the group consisting of:



45. The compound of any one of claims 31-33, wherein L is $-(CH_2)_m-$.

46. The compound of any one of claims 31-45, wherein m is 0.

47. The compound of any one of claims 31-45, wherein m is 2.


48. The compound of any one of claims 31-45, wherein m is 3.

49. The compound of any one of claims 31-48, wherein R^1 is selected from the group consisting of halogen, C_1 - C_5 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_5 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted with one, two, or three independent occurrences of fluorine.

50. The compound of any one of claims 31-49, wherein R^1 is CF_3 .

51. The compound of any one of claims 31-49, wherein R^1 is CF_2H .

52. The compound of any one of claims 31-49, wherein R^1 is selected from the group consisting of chloro, bromo, and fluoro.
53. The compound of claim 52, wherein R^1 is bromo.
54. The compound of any one of claims 31-49, wherein R^1 is cyclopropyl.
55. The compound of any one of claims 31-54, wherein R^2 is selected from the group consisting of C_3 - C_5 cycloalkyl, C_1 - C_5 alkyl, halogen, cyano, C_2 - C_5 alkenyl, and C_2 - C_5 alknlyl, wherein C_3 - C_5 cycloalkyl, C_1 - C_5 alkyl, C_2 - C_5 alkenyl, and C_2 - C_5 alknlyl may be optionally substituted with one, two, or three independent occurrences of fluorine.
56. The compound of any one of claims 31-55, wherein R^2 is selected from the group consisting of C_{1-2} alkyl and C_{3-4} cycloalkyl.
57. The compound of any one of claims 31-56, wherein R^3 is selected from the group consisting of H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine.
58. The compound of any one of claims 31-57, wherein R^L is cyclobutyl.
59. The compound of any one of claims 31-58, wherein R^L is $NR^{11}R^{12}$.




60. The compound of any one of claims 31-59, wherein R^L is $\left(\begin{array}{c} \text{---} \\ | \\ R^{34} \text{---} C \text{---} U \text{---} C \text{---} R^{34} \\ | \quad | \\ R^{34} \quad V \quad R^{34} \end{array} \right)_q$, wherein each C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl may be optionally substituted by 1, 2, or 3 independent occurrences of fluorine; U is N or CR^{13} ; V is selected from the group consisting of oxygen, $C(R^{34})_2$, and NR^6 ; r is 0, 1, or 2; q is 1, 2, or 3; R^{13} is selected from H and C_1 - C_3 alkyl; and each occurrence of R^{34} is independently selected from H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine, or two R^{34} are joined together with the carbon to which they are attached to form a C_3 - C_6 cycloalkyl; provided that when r is 0 and q is 1,

then U is not CR¹³ and V is not O, and when r or q is 1, then U is not N and V is not O or NR⁶.

61. The compound of any one of claims 31-60, wherein n is 3.


62. A compound represented by:



Formula IE

or a pharmaceutically acceptable salt thereof, wherein:

ring DD is selected from the group consisting of:




n is 2, 3, or 4;

R¹ is selected from the group consisting of halogen, cyano, C₁-C₅alkyl, and C₃-C₅cycloalkyl, wherein C₁-C₅alkyl and C₃-C₅cycloalkyl may be optionally substituted by one, two or three independent occurrences of fluorine;

R² is selected from the group consisting of C₁-C₂alkyl and C₃-C₄cycloalkyl, and halogen, wherein C₁-C₂alkyl and C₃-C₄cycloalkyl may be optionally substituted by one, two or three independent occurrences of fluorine;

R³ is selected from the group consisting of H, C₁-C₃alkyl, and C₃-C₅cycloalkyl, wherein C₁-C₃alkyl and C₃-C₅cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R⁴ is selected from the group consisting of:



R^9 is selected from the group consisting of H, C₁-C₆alkyl, C₃-C₆cycloalkyl, C(=O) R^5 , SO₂ R^5 , C-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen and heteroaryl, wherein C₁-C₆alkyl and C₃-C₆cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^5 is selected from the group consisting of H, C₁-C₆alkyl, C₃-C₆cycloalkyl, and heterocyclyl, wherein C₁-C₆alkyl and C₃-C₆cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

each occurrence of R^7 is independently selected from the group consisting of H, C₁-C₆alkyl, and C₃-C₆cycloalkyl, wherein C₁-C₆alkyl and C₃-C₆cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine, or two R^7 are joined together with the atom to which they are attached to form oxo;

R^L is selected from the group consisting of C₁-C₆alkyl and C₃-C₆cycloalkyl, $NR^{11}R^{12}$,

and $\left(\begin{array}{c} \text{---} \\ | \\ R^{34} \text{---} U \text{---} R^{34} \\ | \quad | \\ R^{34} \text{---} V \text{---} R^{34} \end{array} \right)_q$, wherein each C₁-C₆alkyl and C₃-C₆cycloalkyl may be optionally substituted by 1, 2, or 3 independent occurrences of fluorine;

U is N or CR¹³;

V is selected from the group consisting of oxygen, C(R³⁴)₂, and NR⁶;

r is 0, 1, or 2;

q is 1, 2, or 3;

R^6 is selected from the group consisting of H, C₁-C₆alkyl, C₃-C₆cycloalkyl, C(=O) R^5 , SO₂ R^5 , C-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen and heteroaryl, wherein C₁-C₆alkyl and C₃-C₆cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^{11} is selected from the group consisting of H, C₁-C₃alkyl, and C₃-C₅cycloalkyl, wherein C₁-C₃alkyl and C₃-C₅cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^{12} is selected from the group consisting of H, C₁-C₃alkyl, and C₃-C₅cycloalkyl, wherein C₁-C₃alkyl and C₃-C₅cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^{13} is selected from H and C₁-C₃alkyl;

each occurrence of R^{34} is independently selected from H, C₁-C₃alkyl, and C₃-C₅cycloalkyl, wherein C₁-C₃alkyl and C₃-C₅cycloalkyl may be optionally substituted by one


or more independent occurrences of fluorine, or two R^{34} are joined together with the carbon to which they are attached to form a C_3 - C_6 cycloalkyl; and

L is $-(C(R^{10})_2)_m-$;

m is 0, 1, 2, or 3;

provided that when m is 0, R^4 is C-linked to the pyrazolyl ring, when m is 1, R^4 is C-linked to L, and when m is 2 or 3, R^4 is N-linked or C-linked to L; and further provided that when r is 0 and q is 1, then U is not CR^{13} and V is not O, and when r or q is 1, then U is not N and V is not O or NR^6 .


63. A compound represented by:



Formula IF

or a pharmaceutically acceptable salt thereof, wherein:

ring DD is selected from the group consisting of:




n is 2, 3, or 4;

R^1 is selected from the group consisting of halogen, cyano, C_1 - C_5 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_5 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one, two or three independent occurrences of fluorine;

R^2 is selected from the group consisting of C_1 - C_2 alkyl and C_3 - C_4 cycloalkyl, and halogen, wherein C_1 - C_2 alkyl and C_3 - C_4 cycloalkyl may be optionally substituted by one, two or three independent occurrences of fluorine;

R^3 is selected from the group consisting of H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^4 is selected from the group consisting of:



R^9 is selected from the group consisting of H, C₁-C₆alkyl, C₃-C₆cycloalkyl, C(=O) R^5 , SO₂ R^5 , C-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen and heteroaryl, wherein C₁-C₆alkyl and C₃-C₆cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^5 is selected from the group consisting of H, C₁-C₆alkyl, C₃-C₆cycloalkyl, and heterocyclyl, wherein C₁-C₆alkyl and C₃-C₆cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

each occurrence of R^7 is independently selected from the group consisting of H, C₁-C₆alkyl, and C₃-C₆cycloalkyl, wherein C₁-C₆alkyl and C₃-C₆cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine, or two R^7 are joined together with the atom to which they are attached to form oxo;

R^L is selected from the group consisting of C₁-C₆alkyl and C₃-C₆cycloalkyl, NR¹¹R¹²,

and $\left(\begin{array}{c} \text{---} \\ \text{R}^{34} \text{---} \text{U} \text{---} \text{R}^{34} \\ \text{R}^{34} \text{---} \text{V} \text{---} \text{R}^{34} \end{array} \right)_q$, wherein each C₁-C₆alkyl and C₃-C₆cycloalkyl may be optionally substituted by 1, 2, or 3 independent occurrences of fluorine;

U is N or CR¹³;

V is selected from the group consisting of oxygen, C(R³⁴)₂, and NR⁶;

r is 0, 1, or 2;

q is 1, 2, or 3;

R^6 is selected from the group consisting of H, C₁-C₆alkyl, C₃-C₆cycloalkyl, C(=O) R^5 , SO₂ R^5 , C-linked heterocyclyl having at least one nitrogen and optionally having an additional ring nitrogen or oxygen and heteroaryl, wherein C₁-C₆alkyl and C₃-C₆cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^{11} is selected from the group consisting of H, C₁-C₃alkyl, and C₃-C₅cycloalkyl, wherein C₁-C₃alkyl and C₃-C₅cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^{12} is selected from the group consisting of H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine;

R^{13} is selected from H and C_1 - C_3 alkyl;

each occurrence of R^{34} is independently selected from H, C_1 - C_3 alkyl, and C_3 - C_5 cycloalkyl, wherein C_1 - C_3 alkyl and C_3 - C_5 cycloalkyl may be optionally substituted by one or more independent occurrences of fluorine, or two R^{34} are joined together with the carbon to which they are attached to form a C_3 - C_6 cycloalkyl; and

L is $-(C(R^{10})_2)_m$;

m is 0, 1, 2, or 3;

provided that when m is 0, R^4 is C-linked to the pyrazolyl ring, when m is 1, R^4 is C-linked to L, and when m is 2 or 3, R^4 is N-linked or C-linked to L; and further provided that when r is 0 and q is 1, then U is not CR^{13} and V is not O, and when r or q is 1, then U is not N and V is not O or NR^6 .

64. A compound selected from the group consisting of: N-(3-((5-cyclopropyl-2-((3-methyl-1-(piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-cyclopropyl-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-cyclopropyl-2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)pivalamide, N-(3-((5-bromo-2-((2-isopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-cyclopropyl-2-((2-isopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((1-(1-amino-2-methyl-1-oxopropan-2-yl)-3-methyl-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((1-(2-cyanopropan-2-yl)-3-methyl-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((4-methyl-6-(4-methylpiperazin-1-yl)pyridin-3-yl)amino)-5-(trifluoromethyl)pyridin-4-

yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-chloro-2-((2-isopropoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-chloro-2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)-N-methylcyclobutanecarboxamide, N-(3-((5-chloro-2-((2-methyl-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-N-methylcyclobutanecarboxamide, N-methyl-N-(3-((2-((2-methyl-4-(piperidin-4-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-chloro-2-((2-methyl-4-(1-methylpiperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-N-methylcyclobutanecarboxamide, N-methyl-N-(3-((2-((2-methyl-4-(1-methylpiperidin-4-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((1-(1-cyclopropylpiperidin-4-yl)-3-methyl-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-N-methylcyclobutanecarboxamide, N-(3-((2-((3-methyl-1-(piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((1-(1-isopropylpiperidin-4-yl)-3-methyl-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((1-(1-isobutylpiperidin-4-yl)-3-methyl-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-bromo-2-((3-methyl-1-(1-d3-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((3-methyl-1-(1-d3-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((4-methyl-6-(4-methylpiperazin-1-yl)pyridin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((4-methyl-6-morpholinopyridin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-isopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-cyclopropyl-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-bromo-2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-

yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-ethyl-4-(5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((4-(1,4-diazabicyclo[3.2.1]octan-4-yl)-2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-ethyl-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-(difluoromethyl)-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-3,3-difluorocyclobutane-1-carboxamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)isobutyramide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)pivalamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclopropanecarboxamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)tetrahydrofuran-3-carboxamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)tetrahydro-2H-pyran-4-carboxamide, N-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)tetrahydrofuran-3-carboxamide, N-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)tetrahydro-2H-pyran-4-carboxamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-N-methylcyclobutanecarboxamide, N-(3-((2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-N-methylcyclobutanecarboxamide, N-(3-((2-((2-ethyl-4-(5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-N-methylcyclobutanecarboxamide, N-(3-((2-((4-(1,4-

diazabicyclo[3.2.1]octan-4-yl)-2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-N-methylcyclobutanecarboxamide, N-(3-((2-((2-ethyl-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-N-methylcyclobutanecarboxamide, N-(3-((5-(difluoromethyl)-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-N-methylcyclobutanecarboxamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-3,3-difluoro-N-methylcyclobutane-1-carboxamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-N-methylisobutyramide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-N-methylpivalamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-N-methyloxetane-3-carboxamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-N-methyltetrahydrofuran-3-carboxamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-N-methyltetrahydro-2H-pyran-4-carboxamide, N-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-N-methylcyclobutanecarboxamide, N-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-N-methyloxetane-3-carboxamide, N-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-N-methyltetrahydrofuran-3-carboxamide, N-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-N-methyltetrahydro-2H-pyran-4-carboxamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1-methylazetidine-3-carboxamide, N-(3-((2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1-methylazetidine-3-carboxamide, N-(3-((2-((2-ethyl-4-(5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1-methylazetidine-3-carboxamide, N-(3-((2-((4-(1,4-diazabicyclo[3.2.1]octan-4-yl)-2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1-methylazetidine-3-carboxamide, N-(3-((2-((2-ethyl-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1-methylazetidine-3-carboxamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-N,1-dimethylazetidine-3-carboxamide, N-(3-((5-chloro-2-((2-ethyl-4-(4-methylpiperazin-1-

yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1-methylazetidine-3-carboxamide, N-(3-((5-chloro-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-N,1-dimethylazetidine-3-carboxamide, N-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1-methylazetidine-3-carboxamide, N-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-N,1-dimethylazetidine-3-carboxamide, N-(3-((2-bromo-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-bromo-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-bromo-4-(5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((4-(1,4-diazabicyclo[3.2.1]octan-4-yl)-2-bromophenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-bromo-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-bromo-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(difluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-chloro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-chloro-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-chloro-4-(5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((4-(1,4-diazabicyclo[3.2.1]octan-4-yl)-2-chlorophenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-chloro-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-chloro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(difluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-cyano-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-cyano-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(difluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((4-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-(difluoromethyl)-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-

yl)phenyl)amino)-5-(difluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-N-methylcyclobutanecarboxamide, N-(3-((5-chloro-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyridin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyridin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-(difluoromethyl)-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyridin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidine-1-carboxamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-N-methylazetidine-1-carboxamide, 3-(3-((2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,1-dimethylurea, 1-(3-((2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3,3-trimethylurea, N-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)azetidine-1-carboxamide, N-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)pyrrolidine-1-carboxamide, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-3,3-dimethylazetidine-1-carboxamide, 3-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,1-dimethylurea, N-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-2,2-dimethylazetidine-1-carboxamide, 3-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,1-dimethylurea, 1-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,3,3-trimethylurea, N-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((1-(2-(dimethylamino)ethyl)-3-methyl-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((3-methyl-1-(1-methylpyrrolidin-3-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-bromo-2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-

yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-chloro-2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)tetrahydrofuran-3-carboxamide, N-methyl-N-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-bromo-2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)-N-methylcyclobutanecarboxamide, N-(3-((5-chloro-2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)-N-methylcyclobutanecarboxamide, N-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)tetrahydro-2H-pyran-4-carboxamide, N-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-(3-((2-((1-(2-(dimethylamino)ethyl)-3-methyl-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-(3-((2-((3-methyl-1-(1-methylpyrrolidin-3-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-methyl-N-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-(3-((2-((1-(2-(dimethylamino)ethyl)-3-methyl-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-N-methyl-oxetane-3-carboxamide, N-methyl-N-(3-((2-((3-methyl-1-(1-methylpyrrolidin-3-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-(3-((5-bromo-2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, 1-methyl-N-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidine-3-carboxamide, N-(3-((2-((1-(2-(dimethylamino)ethyl)-3-methyl-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1-methylazetidine-3-carboxamide, 1-methyl-N-(3-((2-((3-methyl-1-(1-methylpyrrolidin-3-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidine-3-carboxamide, N,1-dimethyl-N-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidine-3-carboxamide, N-(3-((2-((1-(2-(dimethylamino)ethyl)-3-methyl-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-N,1-dimethylazetidine-3-carboxamide, N,1-dimethyl-N-(3-((2-((3-methyl-1-(1-methylpyrrolidin-3-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-

yl)amino)propyl)azetidine-3-carboxamide, N-(3-((5-bromo-2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)-1-methylazetidine-3-carboxamide, N-(3-((5-(difluoromethyl)-2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-(difluoromethyl)-2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)-N-methylcyclobutanecarboxamide, N-(3-((5-(difluoromethyl)-2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-(3-((5-(difluoromethyl)-2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)-1-methylazetidine-3-carboxamide, N-(3-((2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-methyl-N-(3-((2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-methyl-N-(3-((2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, 1-methyl-N-(3-((2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidine-3-carboxamide, N,1-dimethyl-N-(3-((2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidine-3-carboxamide, N-(3-((5-(difluoromethyl)-2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-(difluoromethyl)-2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-(3-((5-(difluoromethyl)-2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)-1-methylazetidine-3-carboxamide, N-(3-((5-bromo-2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-bromo-2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-(3-((5-bromo-2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)-1-methylazetidine-3-carboxamide, N-(3-((5-chloro-2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-

yl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((5-chloro-2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-(3-((5-chloro-2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)-1-methylazetidine-3-carboxamide, N-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)isobutyramide, N-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)pivalamide, N-methyl-N-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)pivalamide, N-(3-((5-bromo-2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)pivalamide, N-(3-((5-bromo-2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)pivalamide, 3,3-difluoro-N-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutane-1-carboxamide, 3,3-difluoro-N-(3-((2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutane-1-carboxamide, 3,3-difluoro-N-methyl-N-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutane-1-carboxamide, 3,3-difluoro-N-methyl-N-(3-((2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutane-1-carboxamide, N-(3-((5-(difluoromethyl)-2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)-3,3-difluorocyclobutane-1-carboxamide, N-(3-((5-bromo-2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)-3,3-difluorocyclobutane-1-carboxamide, N-(3-((5-bromo-2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)-3,3-difluorocyclobutane-1-carboxamide, N-(3-((5-chloro-2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)-3,3-difluorocyclobutane-1-carboxamide, N-(3-((2-((5-methyl-1-(1-methylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((5-methyl-2-(1-methylpiperidin-4-yl)-2H-1,2,3-triazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((5-methyl-2-(1-methylpiperidin-4-yl)thiazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((5-methyl-2-(1-methylpiperidin-4-

yl)oxazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((4-methyl-2-(1-methylpiperidin-4-yl)thiazol-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((4-methyl-2-(1-methylpiperidin-4-yl)oxazol-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((5-methyl-2-(4-methylpiperazin-1-yl)thiazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((5-methyl-2-(4-methylpiperazin-1-yl)oxazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((4-methyl-2-(4-methylpiperazin-1-yl)thiazol-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((4-methyl-2-(4-methylpiperazin-1-yl)oxazol-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((5-methyl-1-(1-methylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-(3-((2-((5-methyl-2-(1-methylpiperidin-4-yl)-2H-1,2,3-triazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-(3-((2-((5-methyl-2-(1-methylpiperidin-4-yl)thiazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-(3-((2-((5-methyl-2-(1-methylpiperidin-4-yl)oxazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-(3-((2-((4-methyl-2-(1-methylpiperidin-4-yl)oxazol-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-(3-((2-((4-methyl-2-(1-methylpiperidin-4-yl)thiazol-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-(3-((2-((5-methyl-2-(4-methylpiperazin-1-yl)thiazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-(3-((2-((5-methyl-2-(4-methylpiperazin-1-yl)oxazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-(3-((2-((4-methyl-2-(4-methylpiperazin-1-yl)thiazol-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, N-(3-((2-((4-methyl-2-(4-methylpiperazin-1-yl)thiazol-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)oxetane-3-carboxamide, 3,3-difluoro-N-(3-((2-((5-methyl-2-(1-methylpiperidin-4-yl)-2H-1,2,3-triazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)cyclobutane-1-carboxamide, 1-methyl-N-(3-((2-((5-methyl-1-(1-methylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidine-3-carboxamide, 1-methyl-N-(3-((2-

((5-methyl-2-(1-methylpiperidin-4-yl)-2H-1,2,3-triazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidine-3-carboxamide, 1-methyl-N-(3-((2-((5-methyl-2-(1-methylpiperidin-4-yl)thiazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidine-3-carboxamide, 1-methyl-N-(3-((2-((5-methyl-2-(1-methylpiperidin-4-yl)oxazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidine-3-carboxamide, 1-methyl-N-(3-((2-((4-methyl-2-(1-methylpiperidin-4-yl)thiazol-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidine-3-carboxamide, 1-methyl-N-(3-((2-((4-methyl-2-(1-methylpiperidin-4-yl)oxazol-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidine-3-carboxamide, 1-methyl-N-(3-((2-((5-methyl-2-(4-methylpiperazin-1-yl)thiazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidine-3-carboxamide, 1-methyl-N-(3-((2-((5-methyl-2-(4-methylpiperazin-1-yl)oxazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidine-3-carboxamide, 1-methyl-N-(3-((2-((4-methyl-2-(4-methylpiperazin-1-yl)thiazol-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidine-3-carboxamide, 1-methyl-N-(3-((2-((4-methyl-2-(4-methylpiperazin-1-yl)oxazol-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidine-3-carboxamide, N-(3-((2-((5-methyl-2-(1-methylpiperidin-4-yl)-2H-1,2,3-triazol-4-yl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((5-methyl-2-(1-methylpiperidin-4-yl)thiazol-4-yl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((5-methyl-2-(1-methylpiperidin-4-yl)oxazol-4-yl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((4-methyl-2-(1-methylpiperidin-4-yl)thiazol-5-yl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((4-methyl-2-(1-methylpiperidin-4-yl)oxazol-5-yl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)cyclobutanecarboxamide, N-methyl-N-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)oxetane-3-carboxamide, 1-methyl-N-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-

yl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)azetidine-3-carboxamide, N-(3-((2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)cyclobutanecarboxamide, N-(3-((2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)oxetane-3-carboxamide, 1-methyl-N-(3-((2-((3-methyl-1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)azetidine-3-carboxamide, N-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidine-1-carboxamide, 1,1-dimethyl-3-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)urea, N-methyl-N-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidine-1-carboxamide, 1,1,3-trimethyl-3-(3-((2-((3-methyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)urea, and pharmaceutically acceptable salts, enantiomers, stereoisomers, and tautomers thereof.

65. A pharmaceutical composition comprising a compound of any one of claims 1-64 and a pharmaceutically acceptable excipient.

66. A pharmaceutical composition comprising a compound of any one of claims 1-64, one or more additional therapeutic agents, and a pharmaceutically acceptable excipient.

67. The pharmaceutical composition of claim 66, wherein the composition comprises one additional therapeutic agent.

68. The pharmaceutical composition of claim 66 or claim 67, wherein the additional therapeutic agent is a MAPKAP pathway inhibitor.

69. The pharmaceutical composition of claim 68, wherein the MAPKAP pathway inhibitor is selected from the group consisting of a MEK inhibitor, an ERK inhibitor, a RAF inhibitor, and a Ras inhibitor.

70. The pharmaceutical composition of claim 69, wherein the MEK inhibitor is selected from the group consisting of trametinib, selumetinib, cobimetinib, binimetinib, and pharmaceutically acceptable salts thereof.

71. The pharmaceutical composition of claim 69, wherein the ERK inhibitor is selected from the group consisting of ulixertinib, SCH772984, LY3214996, ravoxertinib, VX-11e, and pharmaceutically acceptable salts thereof.

72. The pharmaceutical composition of claim 69, wherein the RAF inhibitor is selected from the group consisting of LY3009120, LXH254, RAF709, dabrafenib, vemurafenib, and pharmaceutically acceptable salts thereof.

73. The pharmaceutical composition of claim 69, wherein the Ras inhibitor is selected from the group consisting of AMG-510, MRTX849, and pharmaceutically acceptable salts thereof.

74. The pharmaceutical composition of claim 66 or claim 67, wherein the additional therapeutic agent is a chemotherapeutic agent.

75. The pharmaceutical composition of claim 74, wherein the chemotherapeutic agent is selected from the group consisting of anti-tubulin agents, vinorelbine, DNA-alkylating agents, DNA intercalating agents, 5-fluorouracil, capecitabine, cytarabine, decitabine, 5-aza cytidine, gemcitabine, and methotrexate.

76. A method of treating a tumor in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of any one of claims 1-64.

77. A method of treating a cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of any one of claims 1-64.

78. The method of claim 77, wherein the cancer is selected from the group consisting of gastrointestinal stromal tumors, esophageal cancer, gastric cancer, melanomas, gliomas, glioblastomas, ovarian cancer, bladder cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, renal cancers, hepatic cancers, osteosarcomas, multiple myelomas,

cervical carcinomas, cancers that are metastatic to bone, papillary thyroid carcinoma, non-small cell lung cancer, and colorectal cancers.

79. The method of claim 77 or claim 78, wherein the cancer is metastatic.

80. A method of treating a disorder selected from the group consisting of melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, renal cancers, hepatic cancers, osteosarcomas, multiple myelomas, cervical carcinomas, cancers that are metastatic to bone, papillary thyroid carcinoma, non-small cell lung cancer, and colonic cancers in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of any one of claims 1-64.

81. The method of any one of claims 76-80, further comprising administering to the patient one or more additional therapeutic agents.

82. The method of claim 81, wherein the additional therapeutic agent is a MAPKAP pathway inhibitor.

83. The method of claim 82, wherein the MAPKAP pathway inhibitor is selected from the group consisting of a MEK inhibitor, an ERK inhibitor, a RAF inhibitor, and a Ras inhibitor.

84. The method of claim 83, wherein the MEK inhibitor is selected from the group consisting of trametinib, selumetinib, cobimetinib, binimetinib, and pharmaceutically acceptable salts thereof.

85. The method of claim 83, wherein the ERK inhibitor is selected from the group consisting of ulixertinib, SCH772984, LY3214996, ravoxertinib, VX-11e, and pharmaceutically acceptable salts thereof.

86. The method of claim 83, wherein the RAF inhibitor is selected from the group consisting of LY3009120, LXH254, RAF709, dabrafenib, vemurafenib, and pharmaceutically acceptable salts thereof.

87. The method of claim 83, wherein the Ras inhibitor is selected from the group consisting of AMG-510, MRTX849, and pharmaceutically acceptable salts thereof.
88. The method of claim 83, wherein the additional therapeutic agent is a chemotherapeutic agent.
89. The method of claim 88, wherein the chemotherapeutic agent is a selected from the group consisting of anti-tubulin agents, vinorelbine, DNA-alkylating agents, DNA intercalating agents, 5-fluorouracil, capecitabine, cytarabine, decitabine, 5-aza cytidine, gemcitabine, and methotrexate.